SIG: Real-World Evidence (RWE) Collaborative

 View Only
Back to discussions
Expand all | Collapse all

Extension to survey end date: Current practice for RWD source identification and feasibility assessment for pharmacoepidemiology - Invitation to participate in survey

  • 1.  Extension to survey end date: Current practice for RWD source identification and feasibility assessment for pharmacoepidemiology - Invitation to participate in survey

    Posted 12-16-2022 08:22

    If you are a researcher who uses Real-world data (RWD) sources, we would like to remind you of our invitation for you released earlier this month to complete a survey to understand the Current practice for RWD source identification and feasibility assessment for pharmacoepidemiology.

    We have extended the survey end date . Please complete the survey by January 16th, 2023.

    Real-world data (RWD) has been extensively used for regulatory-mandated post-marketing safety and effectiveness studies as well as reimbursement decisions over the last several years. Most recently, there has been an increasing reliance on use of RWD for effectiveness as part of the submissions, NDAs and BLAs, and label expansion. In parallel, there has been an increase in the number of potential RWD sources available to researchers, and newly released guidance documents related to suitability of RWD sources.

    To aid researchers using RWD sources, we are preparing an ISPE-supported manuscript that aims to provide practical guidance on the identification and feasibility assessment of RWD sources. The following survey is intended to explore current practice in this context. Your input will be very much appreciated and valued to support ISPE members.

    This survey should take no more than 30 minutes to complete. Your participation is entirely voluntary and all information provided will remain confidential.

    Please click here to complete the survey.  

     

    Dony Patel , MSc, PhD.

    Deborah Layton, drdeborahlayton@outlook.com

    ISPE Education Committee (EC) Chair



    ------------------------------
    Dony Patel PhD, MSc
    Director, Global Database Studies
    IQVIA (UK)
    Orpington
    +44 07305285871
    ------------------------------


  • 2.  RE: Extension to survey end date: Current practice for RWD source identification and feasibility assessment for pharmacoepidemiology - Invitation to participate in survey

    Posted 01-27-2023 10:23

     Hi All

    This is a quick follow up on my earlier request. We close the survey last week , so thanks so much to those that could complete it.

    There are some very interest findings, I think, on how we identify and assess RWD which will be good to present at our August conference for the ISPE community. Please look out for it!

    We may indeed follow-up with some of you that allowed us to re-contact you for more details.

    Much appreciated.

    Dony Patel , Deborah Layton,  ISPE Education Committee (EC) Chair





    ------------------------------
    Dony Patel PhD, MSc
    Director, Global Database Studies
    IQVIA
    Orpington
    +1 (617) 621-1600
    ------------------------------

    Original Message